araag2/HINT huggingface dataset:
Clinical trial NCT02004392 (phase 3, status: terminated)
Conditions: alzheimer's disease, dementia
ICD codes: G30.8, G30.9, G30.0, G30.1, G31.09, G31.83, F01.50, F01.51, F03.90, F03.91, F18.17
Drugs: evp-6124
SMILES: ClC1=C2SC(=CC2=CC=C1)C(=O)N[C@H]1CN2CCC1CC2
Reason stopped: 
    study has been suspended due to clinical hold.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects of any race, aged ≥55 and ≤85 years at time of entry into
             study EVP-6124-024 or EVP-6124-025

          -  Informed consent form (ICF) for this extension study signed by the subject or legally
             acceptable representative and an ICF signed by the support person/caregiver before
             initiation of any study-specific procedures

          -  Successful completion (Day 182) of study EVP-6124-024 or EVP-6124-025

          -  No clinically significant change in the judgment of the investigator in the subject's
             medical status during study EVP-6124-024 or EVP-6124-025

          -  In the judgment of the investigator, extension treatment is in the best interest of
             the subject

          -  Fertile, sexually active subjects (men and women) must use an effective method of
             contraception during the study. Female subjects and the female partner of male
             subjects must be surgically sterile (hysterectomy or bilateral tubal ligation),
             postmenopausal for at least 1-year, or willing to practice adequate methods of
             contraception if of childbearing potential (defined as consistent use of combined
             effective methods of contraception [including at least 1 barrier method])

          -  Reliable and capable support person/caregiver, who if not living in the same
             household, interacts with the subject approximately 4 times per week and will be
             available to attend clinic visits in person when possible

        Exclusion Criteria:

          -  Significant risk of suicidal or violent behavior in the judgment of the investigator

          -  Adverse events from the previous study (EVP-6124-024 or EVP-6124-025) that have not
             resolved, are moderate or severe, judged to be possibly related or related to study
             drug, and considered by the investigator to be a contraindication to extension study
             participation

          -  Any condition that would make the subject in the judgment of the investigator
             unsuitable for the study

          -  Female subjects who are pregnant, nursing, or planning to become pregnant during the
             extension study
Clinical trial NCT02006641 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: placebo, idalopirdine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC(F)C(F)(F)COC1=CC=CC(CNCCC2=CNC3=CC(F)=CC=C23)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  The patient has a knowledgeable and reliable caregiver.

          -  The patient is an outpatient.

          -  The patient has probable AD.

          -  The patient has mild to moderate AD.

          -  Stable treatment with donepezil.

          -  The patient, if a woman, must have had her last natural menstruation ≥24 months prior
             to baseline, OR be surgically sterile.

          -  The patient, if a man, agrees to protocol-defined use of effective contraception if
             his female partner is of childbearing potential, OR must have been surgically
             sterilised prior to the screening visit.

        Exclusion Criteria:

          -  The patient has evidence of any clinically significant neurodegenerative disease, or
             other serious neurological disorders other than AD.

          -  The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition,
             Text Revision (DSM-IV-TR) Axis I disorder other than AD.

          -  The patient has evidence of clinically significant disease.

          -  The patient's donepezil therapy is likely to be interrupted or discontinued during the
             study.

          -  The patient is currently receiving memantine or has taken memantine within 2 months
             prior to screening.

        Other inclusion and exclusion criteria may apply.
Clinical trial NCT02006654 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: placebo, idalopirdine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC(F)C(F)(F)COC1=CC=CC(CNCCC2=CNC3=CC(F)=CC=C23)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  The patient has a knowledgeable and reliable caregiver.

          -  The patient is an outpatient.

          -  The patient has probable AD.

          -  The patient has mild to moderate AD.

          -  Stable treatment with an AChEI.

          -  The patient, if a woman, must have had her last natural menstruation ≥24 months prior
             to baseline, OR be surgically sterile.

          -  The patient, if a man, agrees to protocol-defined use of effective contraception if
             his female partner is of childbearing potential, OR must have been surgically
             sterilised prior to the screening visit.

        Exclusion Criteria:

          -  The patient has evidence of any clinically significant neurodegenerative disease, or
             other serious neurological disorders other than AD.

          -  The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition,
             Text Revision (DSM-IV-TR) Axis I disorder other than AD.

          -  The patient has evidence of clinically significant disease.

          -  The patient's current AChEI therapy is likely to be interrupted or discontinued during
             the study.

          -  The patient is currently receiving memantine or has taken memantine within 2 months
             prior to screening.

        Other inclusion and exclusion criteria may apply.
Clinical trial NCT02007629 (phase 3, status: completed)
Conditions: hypertension, pulmonary
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: riociguat (adempas, bay63-2521)
SMILES: COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients (18 -75 years of age) with idiopathic, familial, drug/toxin
             induced and associated PAH due to congenital heart disease (Group I / Dana Point
             Classification of PH) demonstrating insufficient response to treatment with PDE-5i for
             at least 3 months

          -  Patients with and without endothelin receptor antagonist (ERA) therapy

          -  World Health Organization Functional Class (WHO FC) III at screening

          -  6-minute walking distance (6MWD) of 165-440 m

          -  Cardiac index <3.0 L/min/m*2.

        Exclusion Criteria:

          -  All types of PH except subtypes of Dana Point Group I specified in the inclusion
             criteria

          -  Evidence of clinically significant restrictive or obstructive parenchymal lung
             diseases

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) <30% predicted

          -  History or active state of serious hemoptysis / pulmonary hemorrhage including those
             managed by bronchial artery embolization

          -  Patients unable to perform a valid 6MWD test

          -  Pregnant women (i.e. positive pregnancy test or other signs of pregnancy), or breast
             feeding women, or women with childbearing potential not using a combination of 2
             effective methods of birth control, for example a combination of condoms with a safe
             and highly effective contraception method (prescription oral contraceptives,
             contraceptive injections, contraceptive patch, intrauterine device) or a double
             barrier method is used throughout the study.
Clinical trial NCT02008227 (phase 3, status: completed)
Conditions: non-squamous non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: atezolizumab, docetaxel
SMILES: CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC

          -  Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens

          -  Disease progression during or following treatment with a prior platinum-containing
             regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease
             recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant
             regimen or combined modality (e.g., chemoradiation) regimen with curative intent

          -  Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Known active or untreated central nervous system (CNS) metastases

          -  Malignancies other than NSCLC within 5 years prior to randomization, with the
             exception of those with a negligible risk of metastasis or death and treated with
             expected curative outcome

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced
             pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening
             chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation
             field (fibrosis) is permitted

          -  Active hepatitis B or hepatitis C

          -  Prior treatment with docetaxel

          -  Prior treatment with cluster of differentiation 137 (CD137) agonists,
             anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA4), anti-programmed death-1
             (anti-PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Clinical trial NCT02008916 (phase 3, status: completed)
Conditions: spondylitis, ankylosing
ICD codes: M08.1, M45.6, M45.2, M45.3, M45.4, M45.5, M45.7
Drugs: secukinumab, placebo secukinumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria: moderate to severe AS, prior radiographic evidence according to the
        Modified NY Criteria (1984), inadequate response to NSAIDs. -- Exclusion criteria:
        pregnancy or lactation, on-going infectious or malignant process on a chest X-ray or MRI,
        previous exposure to IL-17 or IL-17R targeting therapies, previous exposure to any
        biological immunomodulating agent excluding TNF antagonists, previous cell depleting
        therapy.
Clinical trial NCT02008942 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: pl2200 aspirin capsules, enteric-coated aspirin caplets
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Non-Insulin-Dependent Diabetes Mellitus

          -  Adults 21 to 79 years, inclusive

          -  Body mass index between 30 and 40 kg/m2, inclusive

        Exclusion Criteria:

          -  Currently prescribed aspirin or anti-coagulants

          -  Contraindications to aspirin

          -  Significant disease history or active disease other than Non-Insulin-Dependent
             Diabetes Mellitus

          -  Patient requires insulin
Clinical trial NCT02013167 (phase 3, status: terminated)
Conditions: relapsed/refractory b-precursor acute lymphoblastic leukemia
ICD codes: C83.57, C83.50, C91.01, C91.02, C83.52, C83.56, C83.53
Drugs: blinatumomab, standard of care chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        -  Subjects with Philadelphia negative B-precursor ALL, with any of the following:

               -  refractory to primary induction therapy or refractory to salvage therapy,

               -  in untreated first relapse with first remission duration <12 months

               -  in untreated second or greater relapse

               -  relapse at any time after allogeneic HSCT

          -  Subject has received intensive combination chemotherapy for the treatment of ALL for
             initial treatment or subsequent salvage therapy.

          -  Greater than 5% blasts in the bone marrow

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

        Exclusion Criteria

          -  Malignancy other than ALL within 5 years before blinatumomab treatment, except for
             adequately treated selected cancers without evidence of disease

          -  Diagnosis of Burkitt's leukemia according to World Health Organization classification,
             or human immunodeficiency virus (HIV), Hepatitis B or C, or other clinically
             significant disorder

          -  Current relevant central nervous system (CNS) pathology or known or suspected CNS
             involvement

          -  Isolated extramedullary disease

          -  Current autoimmune disease or history of autoimmune disease with potential CNS
             involvement

          -  Autologous HSCT within 6 weeks or allogeneic HSCT within 12 weeks before blinatumomab
             treatment, or eligibility for allogeneic HSCT at the time of enrollment

          -  Active acute grade 2 to 4 graft versus host disease (GvHD) according to Glucksberg et
             al (1974) criteria that required systemic treatment to prevent or treat GvHD 2 weeks
             before blinatumomab treatment

          -  Known exclusion criteria to investigator choice of SOC chemotherapy (per package
             insert)

          -  Cancer chemotherapy or radiotherapy with 2 weeks, or immunotherapy (included CD19
             therapy) within 4 weeks of protocol-specified therapy

          -  Abnormal laboratory values (alanine or aspartate transaminase [ALT or AST] or alkaline
             phosphatase [ALP] ≥ 5 × upper limit of normal [ULN]; total bilirubin or creatinine ≥
             1.5 × ULN), or calculated creatinine clearance < 60 mL/min.
Clinical trial NCT02019420 (phase 3, status: completed)
Conditions: pneumonia
ICD codes: A01.03, A02.22, A54.84, B01.2, B06.81, B77.81, J12.0
Drugs: tedizolid phosphate, linezolid
SMILES: CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[C@H](COP(O)(O)=O)OC1=O, CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Requires IV antibiotic therapy with diagnosis of ventilated nosocomial pneumonia

          -  Gram-positive bacteria on respiratory Gram stain

        Exclusion Criteria:

          -  Pneumonia of community, viral, fungal or parasitic etiology

          -  Structural lung abnormalities

          -  Immunosuppression

          -  Previous antibiotics for > 24 hours

          -  Expected survival of < 72 hours
Clinical trial NCT02019472 (phase 3, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of rheumatoid arthritis (RA) for at least 6 months before screening

          -  Have moderately to severely active RA with at least 8 of 68 tender joints and 6 of 66
             swollen joints, at screening and at baseline

          -  Have previous or current treatment with methotrexate (MTX) and are considered
             intolerant to MTX, and/or are considered inappropriate for treatment with MTX,
             (including MTX-naïve subjects for whom it is inappropriate to administer MTX) and/or
             an inadequate responder to methotrexate

          -  Must not have received MTX or any other non-biologic DMARD including but not limited
             to sulfasalazine, hydroxychloroquine, chloroquine, and bucillamine for at least 2
             weeks prior to the first administration of the study agent

          -  C-reactive protein >= 10.00 mg/L or erythrocyte sedimentation rate >=28 mm/hr at
             screening

        Exclusion Criteria:

          -  Has Functional Class IV as defined by the ACR Classification of Functional Status in
             Rheumatoid Arthritis

          -  Has ever received biologic therapy for RA, including but not limited to the following:
             TNF-alpha inhibitors, tocilizumab, rituximab, anakinra, abatacept

          -  Has ever used tofacitinib therapy or any other JAK inhibitor

          -  Has received intra-articular, intramuscular, or IV corticosteroids for RA, including
             adrenocorticotrophic hormone during the 4 weeks prior to first study agent
             administration

          -  Has received leflunomide within 24 months before the first study agent administration
             and has not undergone a drug elimination procedure, unless the M1 metabolite is
             measured and is undetectable
Clinical trial NCT02022930 (phase 3, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: triamcinolone acetonide
SMILES: [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Have radiographic evidence within the prior 6 months, as shown in the radiology
             reports, of OA grade 2 or 3 using Kellgren-Lawrence Grading for OA.

          -  Symptoms in the index knee for at least 12 months.

          -  Fully ambulatory Subject (ability to perform a 15 meters walk test).

          -  Male and female Subjects 40 through 85 years of age.

        Exclusion Criteria:

          -  BMI >40 kg

          -  Secondary OA (acute knee injury, rheumatoid arthritis, gout, history of joint
             infection, osteonecrosis, chronic fibromyalgia) or other chronic autoimmune disease.

          -  Intra articular steroid therapy in last 3 months

          -  Intra articular viscosupplementation in last 6 months
Clinical trial NCT02025621 (phase 3, status: completed)
Conditions: coronary artery bypass grafting, mitral valve surgery, low cardiac output syndrome
ICD codes: I25.84, I25.41, I25.42, Z98.61, Q24.5, T46.3X6S, I25.82
Drugs: levosimendan, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented LVEF ≤35% measured by ventriculogram, echocardiogram (ECHO), nuclear scan,
             or MRI within 60 days before surgery.

          -  Scheduled or urgent 1) CABG surgery, 2)CABG with aortic valve surgery, 3) CABG with
             mitral valve surgery, or 4) mitral valve surgery with or without other valves

          -  Surgery will employ CPB pump

          -  Signed (by the subjects or their legally acceptable representatives) informed consent
             document indicating that they understand the purpose of and procedures required for
             the study and are willing to participate in the study

        Exclusion Criteria:

          -  Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive
             pericarditis, pericardial tamponade, or other conditions in which cardiac output is
             dependent on venous return.

          -  Evidence of systemic bacterial, systemic fungal, or viral infection within 72 hours
             before surgery.

          -  Dialysis at randomization (either hemodialysis, peritoneal dialysis, continuous
             venovenous hemofiltration, or ultrafiltration).

          -  Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2.

          -  Weight ≥ 170 kg.

          -  Patients whose SBP cannot be managed to ensure SBP > 90 mmHg at initiation of study
             drug.

          -  Heart rate ≥ 120 bpm, persistent for at least 10 minutes screening and unresponsive to
             treatment.

          -  Hemoglobin < 80 g/L.

          -  Serum potassium < 3.5 mmol/L and > 5.5 mmol/L at baseline.

          -  A history of Torsades de Pointes.

          -  Mechanical assist device (IABP, LVAD, ECMO) in the patient at the start of surgery or
             pre-planned to be inserted during surgery before coming off CPB.

          -  Patients with aortal femoral occlusive disease that would prohibit use of IABP unless
             VAD or ECMO not available.

          -  Liver dysfunction Child Pugh Class B or C

          -  Patients having severely compromised immune function

          -  Pregnant, suspected to be pregnant, or breast-feeding.

          -  Received an experimental drug or used an experimental medical device in previous 30
             days.

          -  Known allergic reaction or sensitivity to Levosimendan or excipients.

          -  Received commercial Levosimendan within 30 days before the planned start of study
             drug.

          -  Employees of the investigator or study center, with direct involvement in the proposed
             study or other studies under the direction of that investigator or study center, as
             well as family members of the employees or the investigator.
Clinical trial NCT02025725 (phase 3, status: completed)
Conditions: diabetic gastroparesis
ICD codes: K31.84
Drugs: metoclopramide nasal spray, placebo nasal spray
SMILES: CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Non pregnant, non lactating female subjects between the ages of 18 and 75 years

          -  Willingness and ability to give written informed consent

          -  The ability to read, understand and speak English

          -  Prior diagnosis of Type 1 or Type 2 diabetes

          -  Diagnosis of diabetic gastroparesis with confirmation of delayed gastric emptying

          -  A mean daily gastroparesis symptom score of ≥1.4 and ≤3.5 prior to randomization

          -  Subjects of childbearing potential must agree to use contraception

          -  Willingness to discontinue current treatment for diabetic gastroparesis and to avoid
             all proscribed (excluded) medications, as specified by the protocol, for the duration
             of the study

        Exclusion Criteria:

          -  Gastric bypass, gastric banding, gastric pacemaker, post surgical causes of
             gastroparesis and disorders known to be associated with abnormal gastrointestinal
             motility

          -  A history of allergic or adverse responses, including, but not limited to, acute
             dystonic reactions and tardive dyskinesia, to metoclopramide or any comparable or
             similar product

          -  A history of, or physical findings suggestive of, tardive dyskinesia

          -  A history of epilepsy or currently using and unwilling or unable stop other drugs
             known to be associated with extrapyramidal reactions at screening

          -  A history of allergy to any of the ingredients in the study drug formulation

          -  A history of organ transplant, chronic pancreatitis, gross malabsorptive syndromes,
             celiac disease, active inflammatory bowel disease (IBD), or symptomatic irritable
             bowel syndrome (IBS)

          -  Malignancy (with the exception of treated squamous cell or basal cell carcinoma of the
             skin) currently present, initially diagnosed or recurring within five (5) years of
             screening

          -  Renal dysfunction calculated as creatinine clearance (CrCl) <40 mL/min at screening

          -  Hemoglobin A1c >11.5% at screening

          -  Subjects who are trying to conceive, are pregnant, or are lactating